Skip to content

Not Your Father’s FDA

October 20, 2017

“This is not your father’s FDA.” That was the conclusion I drew from NORD’s Rare Diseases and Orphan Products Breakthrough Summit, a two-day conference that included presentations by Commissioner Gottlieb, and the directors of CDER, CBER, and CDRH, as well as by leaders at the review division level. … READ MORE …

Advocacy at a Glance

October 20, 2017

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

The FDA Deserves Special Consideration at Budget-Time

October 13, 2017

Twice in recent months, I have had the opportunity to describe FDA funding to advocates who focus on the budgets of other federal agencies. … READ MORE …

Advocacy at a Glance

October 13, 2017

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

FDA Stakeholders Need to Start to “Up Our Game”

October 6, 2017

With a Continuing Resolution funding the government from October 1 to December 8, there is no immediate pressure on Congress to pass full year appropriations bills for FY 18. … READ MORE …

Advocacy at a Glance

October 6, 2017

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

Plus ça Change, Plus c’est la Même Chose

September 29, 2017

In last week’s column, I stated that “the Alliance is proud that over a 10-year period we have helped push FDA’s BA funding from $1.5 billion to $2.7 billion.” … READ MORE …